Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301
Read more
Contact MENU

News

Showing posts for — Author: kioradev

01.05.22

Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference

SALT LAKE CITY, UT, Jan 05, 2022 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the H.C. Wainwright Bioconnect Virtual Conference January 10-13, 2022. Brian M Strem, Ph.D., President...
Read more
10.26.21

EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.

EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline WALTHAM, MA, October 26, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical...
Read more
Eye Exam
09.09.21

EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WALTHAM, MA, September 9, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that...
Read more
09.08.21

EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers -Trial remains on track with topline data expected in Q4 2021- WALTHAM,...
Read more
08.12.21

EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update

WALTHAM, MA, August 12, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a...
Read more
08.10.21

EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

WALTHAM, MA, August 10, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a...
Read more
07.26.21

EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer

-EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform- WALTHAM, MA, July 26, 2021 – EyeGate...
Read more
05.12.21

EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

- PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21- - OBG: U.S. IND submission and initiation of Phase...
Read more